%0 Journal Article
%T The recommendations of Chinese Parkinson¡¯s disease and movement disorder society consensus on therapeutic management of Parkinson¡¯s disease
%A Anmu Xie
%A Baorong Zhang
%A Beisha Tang
%A Chunfeng Liu
%A Guoguang Peng
%A Haibo Chen
%A Huifang Shang
%A Jian Wang
%A Lijuan Wang
%A Ming Shao
%A Mingwei Wang
%A Pingyi Xu
%A Piu Chan
%A Qin Xiao
%A Shengdi Chen
%A Shenggang Sun
%A Tao Feng
%A Weidong Le
%A Xianwen Chen
%A Xiaochun Chen
%A Xingyue Hu
%A Xinhua Wan
%A Yan Cheng
%A Yiming Liu
%A Zhenfu Wang
%A Zhenguo Liu
%J Archive of "Translational Neurodegeneration".
%D 2016
%R 10.1186/s40035-016-0059-z
%X Parkinson¡¯s disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson¡¯s Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved
%K Parkinson¡¯s disease
%K Treatment guideline
%K optimal therapeutic options
%K China
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928283/